Buzz: GSK plots board coup in HGS flank attack

Forget the usual thin-end-of-the-wedge proxy-fight strategy. Rather than nominating a few directors to push its buyout agenda at Human Genome Sciences ($HGSI), GlaxoSmithKline ($GSK) plans a campaign to sweep the whole board out, Reuters reports. That would clear the way for its $2.6 billion hostile bid. Report